GO:0016603 glutaminyl-peptide cyclotransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016603 describes the enzymatic activity that converts an N-terminal L-glutaminyl residue of a peptide into a pyroglutamate (5-oxo-L-prolyl) residue with release of ammonium.
• The activity is carried out by glutaminyl cyclases (QPCT, QPCTL) and related proteins that generate N-terminal pyroglutamate, a modification that stabilizes peptides and modulates their biological function [5,6].
• QPCT and QPCTL are implicated in Alzheimer's disease, cancer immune evasion, and inflammatory conditions, making them attractive therapeutic targets [6,7,8].
• In cancer, QPCTL-mediated pyroglutamation of CD47 and butyrophilin molecules influences macrophage phagocytosis and Vγ9Vδ2 T-cell killing, linking the enzyme to immune checkpoint regulation [1,3].
• Small-molecule glutaminyl cyclase inhibitors have been developed and tested in preclinical models of Alzheimer's disease and cancer, highlighting the druggability of this activity [7,8].
• CRISPR-based knockout, point-mutation, and knock-in models are essential for dissecting the precise roles of QPCT and QPCTL in physiology and disease [1,2,3].
Description
Glutaminyl-peptide cyclotransferase activity (GO:0016603) is a molecular function that catalyzes the conversion of an N-terminal L-glutaminyl residue in a peptide into an N-terminal 5-oxo-L-prolyl (pyroglutamate) residue, releasing ammonium. This post-translational modification is widespread and affects peptide stability, receptor binding, and immunogenicity. The enzymes responsible, glutaminyl cyclase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), are expressed in various tissues and have been linked to both normal physiology and disease pathology [5,6]. Researchers study GO:0016603 because it represents a critical node in peptide maturation and immune regulation. For example, QPCT-mediated pyroglutamation of amyloid-beta peptides contributes to their aggregation and neurotoxicity in Alzheimer's disease [6,7]. In cancer, QPCTL modifies CD47 and butyrophilin molecules, thereby influencing immune evasion and T-cell responses [1,3]. These findings underscore the importance of understanding the enzymatic mechanism, regulation, and disease relevance of glutaminyl-peptide cyclotransferase activity. This article provides a comprehensive overview of GO:0016603, covering its definition, biological significance, key genes, regulatory mechanisms, disease associations, and experimental approaches including CRISPR-based models. All statements are supported by peer-reviewed literature to ensure accuracy and reproducibility for biomedical researchers.
glutaminyl-peptide cyclotransferase activity At A Glance
| GO ID | GO:0016603 |
|---|---|
| GO term | glutaminyl-peptide cyclotransferase activity |
| Ontology | molecular_function |
| Synonym | glutaminyl cyclase activity, glutaminyl-transfer ribonucleate cyclotransferase activity, glutaminyl-tRNA cyclotransferase activity, L-glutaminyl-peptide gamma-glutamyltransferase (cyclizing) |
| Major function | Catalyzes the conversion of N-terminal L-glutaminyl residues to 5-oxo-L-prolyl (pyroglutamate) residues in peptides, releasing ammonium |
| Reaction | N-terminal L-glutaminyl-[peptide] = N-terminal 5-oxo-L-prolyl-[peptide] + NH4+ |
| Enzymes | QPCT (glutaminyl cyclase), QPCTL (glutaminyl-peptide cyclotransferase-like protein) |
| Cofactors | Zinc ion (Zn2+) is required for catalytic activity |
| Subcellular location | Secreted, Golgi apparatus, and extracellular space |
What Is GO:0016603?
GO:0016603, glutaminyl-peptide cyclotransferase activity, is defined as the catalysis of the reaction: N-terminal L-glutaminyl-[peptide] = N-terminal 5-oxo-L-prolyl-[peptide] + NH4+. In other words, it is an enzymatic activity that cyclizes the N-terminal glutamine of a peptide into a pyroglutamate ring, releasing ammonia. This modification is also known as glutaminyl cyclase activity and is involved in the maturation of numerous bioactive peptides and proteins.
Why Is glutaminyl-peptide cyclotransferase activity Important in Cell Biology?
Glutaminyl-peptide cyclotransferase activity is important because it generates pyroglutamate, a modification that protects peptides from degradation and modulates their interaction with receptors. This activity is critical for the maturation of hormones, chemokines, and amyloid-beta peptides, and its dysregulation is implicated in Alzheimer's disease, cancer, and inflammatory disorders [5,6,7,8]. Understanding this activity provides insights into peptide biology and offers therapeutic opportunities for inhibiting glutaminyl cyclases in disease settings.
• Generates N-terminal pyroglutamate, which stabilizes peptides against aminopeptidase degradation and alters their biological activity.
• QPCT-mediated pyroglutamation of amyloid-beta is linked to increased aggregation and neurotoxicity in Alzheimer's disease [6,7].
• QPCTL modifies CD47, affecting macrophage-mediated phagocytosis and immune surveillance.
• QPCTL-mediated pyroglutamation of butyrophilin molecules influences Vγ9Vδ2 T-cell activation and cancer cell evasion.
• Inhibitors of glutaminyl cyclases are being developed as potential therapeutics for Alzheimer's disease and cancer [7,8].
• The activity is conserved across species, including invertebrates, where it plays roles in immune responses.
• Dysregulation of QPCT has been observed in senescent cells, affecting macrophage clearance of apoptotic cells.
• Glutaminyl cyclase activity is a potential biomarker and target in inflammatory bowel diseases.
What Happens During glutaminyl-peptide cyclotransferase activity?
Substrate Recognition and Binding
In simple terms: The enzyme grabs a peptide that starts with glutamine.
Glutaminyl cyclases (QPCT and QPCTL) specifically recognize peptides with an N-terminal L-glutamine residue. The enzyme binds the peptide substrate in its active site, positioning the glutamine side chain for cyclization. This step is essential for the subsequent catalytic reaction.
Catalytic Cyclization and Ammonium Release
In simple terms: The enzyme turns the glutamine into a ring and releases ammonia.
Once bound, the enzyme catalyzes the intramolecular cyclization of the N-terminal glutamine, forming a 5-oxo-L-prolyl (pyroglutamate) residue and releasing ammonium (NH4+). This reaction is dependent on a zinc ion in the active site, which stabilizes the transition state.
Product Release and Peptide Maturation
In simple terms: The modified peptide is released and is now more stable.
After cyclization, the pyroglutamate-containing peptide is released from the enzyme. The N-terminal pyroglutamate protects the peptide from exopeptidase cleavage and can enhance its binding to receptors or alter its immunogenicity. This maturation step is crucial for the biological function of many peptides [5,6].
Regulation of Enzyme Expression and Activity
In simple terms: Cells control how much enzyme is made and how active it is.
The expression of QPCT and QPCTL is regulated at transcriptional and post-transcriptional levels. Inflammatory cytokines and growth factors can modulate their expression. Additionally, the activity can be influenced by pH and the availability of zinc ions. Dysregulation of this regulation contributes to disease pathology [5,8].
Key Genes Involved in GO:0016603 glutaminyl-peptide cyclotransferase activity
The following genes encode proteins that carry out or regulate glutaminyl-peptide cyclotransferase activity, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| QPCT | Glutaminyl cyclase; catalyzes pyroglutamate formation on peptides | Implicated in Alzheimer's disease; target for inhibitors [6,7] |
| QPCTL | Glutaminyl-peptide cyclotransferase-like protein; modifies CD47 and butyrophilins | Role in cancer immune evasion and immunotherapy [1,3,8] |
| CD47 | Cell surface protein; pyroglutamated by QPCTL | Regulates macrophage phagocytosis; target in cancer |
| BTN3A1 | Butyrophilin; modified by QPCTL | Influences Vγ9Vδ2 T-cell activation |
| BTN2A1 | Butyrophilin; modified by QPCTL | Influences Vγ9Vδ2 T-cell activation |
| APP | Amyloid precursor protein; gives rise to amyloid-beta | Pyroglutamated amyloid-beta in Alzheimer's disease |
| CCL2 | Chemokine; potential substrate of QPCT | Involved in inflammation; may be modified by pyroglutamation |
| CCL7 | Chemokine; potential substrate of QPCT | Involved in inflammation |
| CCL8 | Chemokine; potential substrate of QPCT | Involved in inflammation |
| CCL13 | Chemokine; potential substrate of QPCT | Involved in inflammation |
| CCL16 | Chemokine; potential substrate of QPCT | Involved in inflammation |
| CCL18 | Chemokine; potential substrate of QPCT | Involved in inflammation |
| NPY | Neuropeptide Y; potential substrate of QPCT | Regulates appetite and energy balance |
| GAST | Gastrin; potential substrate of QPCT | Regulates gastric acid secretion |
| TRH | Thyrotropin-releasing hormone; potential substrate of QPCT | Regulates thyroid-stimulating hormone release |
| FGF2 | Fibroblast growth factor 2; potential substrate of QPCT | Involved in cell growth and angiogenesis |
| IL6 | Interleukin-6; potential substrate of QPCT | Involved in inflammation |
How Is glutaminyl-peptide cyclotransferase activity Regulated?
The activity of glutaminyl-peptide cyclotransferase is regulated at multiple levels. Transcriptional regulation of QPCT and QPCTL occurs in response to inflammatory signals and growth factors. Post-translational modifications and the availability of zinc ions can affect enzyme activity. In cancer, QPCTL expression is upregulated and contributes to immune evasion, suggesting regulation by oncogenic pathways. Additionally, senescent cells upregulate the CD47-QPCT/L axis, which suppresses macrophage-mediated corpse removal. These regulatory mechanisms highlight the importance of context-dependent control of this activity.
glutaminyl-peptide cyclotransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| QPCT | Alzheimer's disease | QPCT knockout mice; APP transgenic mice [6,7] |
| QPCTL | Cancer immune evasion | QPCTL knockout cancer cell lines; syngeneic mouse models [1,3,8] |
| CD47 | Cancer phagocytosis | CD47 point-mutant knock-in mice |
| QPCT | Ulcerative colitis | DSS-induced colitis mouse model |
| QPCT | Vibrio alginolyticus infection | Scylla paramamosain (crab) model |
Alzheimer's Disease
Glutaminyl cyclase activity is increased in the brains of Alzheimer's disease patients, where it catalyzes the formation of pyroglutamate-modified amyloid-beta peptides. These modified peptides are more aggregation-prone and neurotoxic, contributing to disease progression [6,7]. Inhibitors of glutaminyl cyclase have been investigated as potential therapeutic agents to reduce amyloid-beta pathology.
Cancer Immune Evasion
QPCTL-mediated pyroglutamation of CD47 and butyrophilin molecules plays a critical role in cancer immune evasion. Pyroglutamated CD47 interacts with SIRPα on macrophages, inhibiting phagocytosis, while modification of butyrophilins affects Vγ9Vδ2 T-cell activation. Targeting QPCTL has emerged as a promising strategy to enhance anti-tumor immunity [1,3,8].
Inflammatory and Infectious Diseases
Glutaminyl-peptide cyclotransferase activity has been implicated in inflammatory conditions such as ulcerative colitis, where inhibition of QPCT alleviates mucosal barrier damage and colonic inflammation in mouse models. In invertebrates, QPCT plays a role in immune responses against bacterial and viral infections.
From glutaminyl-peptide cyclotransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does QPCT loss affect amyloid-beta pyroglutamation? | QPCT knockout mouse |
| Does QPCTL knockout enhance anti-tumor immunity? | QPCTL knockout cancer cell lines and mouse models [1,3] |
| What is the effect of a catalytic-dead QPCT mutation? | Point-mutation knock-in of QPCT active-site residues |
| Can tagged QPCT be used to track localization? | Knock-in of fluorescent or epitope-tagged QPCT |
| Does QPCT overexpression drive inflammation? | Transgenic overexpression of QPCT in mice |
| Which substrates are modified by QPCTL? | Overexpression of QPCTL followed by mass spectrometry |
How to Study the glutaminyl-peptide cyclotransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Fluorogenic activity assay | Enzymatic cyclization activity | Inhibitor screening and kinetic studies |
| Mass spectrometry | Pyroglutamate modification on peptides | Substrate identification and profiling |
| CRISPR-Cas9 knockout | Loss-of-function effects | Target validation in cancer and neurodegeneration [1,3] |
| CRISPR point mutation | Specific catalytic residue function | Mechanistic studies of QPCT |
| CRISPR knock-in | Tagged protein localization and interactions | Live-cell imaging and proteomics |
| Overexpression | Gain-of-function phenotypes | Disease modeling and substrate discovery |
| Immunohistochemistry | Protein expression and localization | Tissue analysis in Alzheimer's disease |
| Flow cytometry | Cell surface CD47 levels | Immune evasion studies |
Enzymatic Activity Assays
Glutaminyl-peptide cyclotransferase activity can be measured using fluorogenic or chromogenic substrates that release a detectable signal upon cyclization. These assays are used to screen inhibitors and characterize enzyme kinetics [5,7].
Mass Spectrometry-Based Proteomics
Mass spectrometry can identify pyroglutamate modifications on peptides and proteins, allowing global profiling of substrates. This approach has been used to map QPCT/QPCTL targets in cells and tissues.
CRISPR-Cas9 Genome Editing
CRISPR-Cas9 knockout, point mutation, and knock-in models enable precise interrogation of QPCT and QPCTL functions in cell lines and animal models. These models help establish causality between enzyme activity and disease phenotypes [1,2,3].
Antibody-Based Detection
Specific antibodies against pyroglutamate-modified peptides or QPCT/QPCTL proteins can be used in Western blotting, immunohistochemistry, and flow cytometry to assess expression and modification levels in tissues.
How CRISPR Can Be Used to Study GO:0016603 glutaminyl-peptide cyclotransferase activity
Knockout
CRISPR-Cas9 knockout of QPCT or QPCTL eliminates enzymatic activity, enabling researchers to study loss-of-function phenotypes. For example, QPCTL knockout in cancer cells enhances macrophage phagocytosis and T-cell killing, validating its role in immune evasion [1,3]. QPCT knockout mice are used to study amyloid-beta pyroglutamation in Alzheimer's disease.
Point Mutation
Point mutations can be introduced into the catalytic domain of QPCT or QPCTL to abrogate enzymatic activity while preserving protein structure. Such models help distinguish between catalytic and non-catalytic functions. For instance, mutation of the zinc-binding residues in QPCT abolishes cyclization activity.
Knock-in
Knock-in of epitope tags or fluorescent proteins into the endogenous QPCT or QPCTL loci allows real-time tracking of protein expression and localization. This approach is valuable for understanding subcellular dynamics and interactions.
Overexpression
Overexpression of QPCT or QPCTL in cell lines or transgenic animals can model gain-of-function states observed in disease. For example, QPCT overexpression in mice exacerbates inflammation in colitis models, and QPCTL overexpression in cancer cells promotes immune evasion.
How EDITGENE Supports glutaminyl-peptide cyclotransferase activity Research
Researchers studying glutaminyl-peptide cyclotransferase activity-related genes often need to determine whether a candidate gene is causally involved in a specific phenotype, such as amyloid-beta pyroglutamation, cancer immune evasion, or inflammatory responses. Precise genome editing tools are essential to establish these causal links and to develop reliable preclinical models.
Contact EDITGENE today to design your custom CRISPR model for glutaminyl-peptide cyclotransferase activity research.
Frequently Asked Questions About glutaminyl-peptide cyclotransferase activity
What is glutaminyl-peptide cyclotransferase activity?
It is an enzymatic activity (GO:0016603) that converts an N-terminal glutamine residue in a peptide to a pyroglutamate residue, releasing ammonium.
What genes encode glutaminyl-peptide cyclotransferase activity?
The main genes are QPCT (glutaminyl cyclase) and QPCTL (glutaminyl-peptide cyclotransferase-like protein) [5,8].
What diseases are associated with glutaminyl-peptide cyclotransferase activity?
It is implicated in Alzheimer's disease, cancer immune evasion, and inflammatory conditions such as ulcerative colitis [1,2,3,6,7,8].
How is glutaminyl-peptide cyclotransferase activity measured?
It can be measured using fluorogenic substrate assays, mass spectrometry, or antibody-based detection of pyroglutamate modifications [5,8].
What are glutaminyl cyclase inhibitors?
Small molecules that inhibit QPCT/QPCTL activity, being developed for Alzheimer's disease and cancer therapy [7,8].
What is the role of QPCTL in cancer?
QPCTL modifies CD47 and butyrophilin molecules, promoting immune evasion by cancer cells [1,3,8].
How does pyroglutamation affect amyloid-beta?
Pyroglutamate-modified amyloid-beta is more aggregation-prone and neurotoxic, contributing to Alzheimer's disease [6,7].
Can CRISPR be used to study glutaminyl-peptide cyclotransferase activity?
Yes, CRISPR knockout, point mutation, and knock-in models are widely used to dissect QPCT/QPCTL functions [1,2,3].
What are the substrates of glutaminyl cyclase?
Substrates include amyloid-beta, chemokines (e.g., CCL2, CCL7), neuropeptides (e.g., NPY), and hormones (e.g., gastrin).
Is glutaminyl-peptide cyclotransferase activity conserved in invertebrates?
Yes, QPCT homologs have been identified in invertebrates like Scylla paramamosain, where they play roles in immune defense.
Conclusion
Glutaminyl-peptide cyclotransferase activity (GO:0016603) is a fundamental enzymatic function that generates N-terminal pyroglutamate on peptides, influencing their stability and biological activity. Its dysregulation is linked to major human diseases, including Alzheimer's disease and cancer, making it a compelling therapeutic target. Continued research using advanced CRISPR models and biochemical assays will further elucidate its mechanisms and pave the way for novel interventions.
References
- 1. Schloesser D et al.. 2023. Senescent cells suppress macrophage-mediated corpse removal via upregulation of the CD47-QPCT/L axis.. J Cell Biol 222(2) PMID: 36459066
- 2. Chen B et al.. 2026. Epi-Berberine Alleviates Ulcerative Colitis, Protects the Intestinal Mucosal Barrier, and Inhibits Colonic Inflammation via Glutaminyl-Peptide Cyclotransferase in a Mouse Model of DSS-Induced Colitis.. Phytother Res 40(5):3009-3026 PMID: 41816944
- 3. Wu Z et al.. 2024. Unsynchronized butyrophilin molecules dictate cancer cell evasion of Vγ9Vδ2 T-cell killing.. Cell Mol Immunol 21(4):362-373 PMID: 38374404
- 4. Wang Z et al.. 2018. Molecular characterization of glutaminyl-peptide cyclotransferase(QPCT)in Scylla paramamosain and its role in Vibrio alginolyticus and white spot syndrome virus (WSSV) infection.. Fish Shellfish Immunol 78:299-309 PMID: 29709591
- 5. Coimbra JRM et al.. 2023. Therapeutic potential of glutaminyl cyclases: Current status and emerging trends.. Drug Discov Today 28(10):103644 PMID: 37244566
- 6. Gunn AP et al.. 2021. Increased glutaminyl cyclase activity in brains of Alzheimer's disease individuals.. J Neurochem 156(6):979-987 PMID: 32614980
- 7. Coimbra JR et al.. 2019. An overview of glutaminyl cyclase inhibitors for Alzheimer's disease.. Future Med Chem 11(24):3179-3194 PMID: 31838899
- 8. Felix Oghenemaro E et al.. 2025. Role of glutaminyl-peptide cyclo-transferase-like protein (QPCTL) in cancer: From molecular mechanisms to immunotherapy.. Gene 937:149153 PMID: 39653089
